New cancer injection shows promise in early trial
NCT ID NCT05727839
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tested an experimental drug called JCXH-211, which is injected directly into tumors. It involved 19 adults with advanced solid tumors that had not responded to standard treatments. The main goals were to check safety and find the right dose, while also watching for any tumor shrinkage.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CUTANEOUS TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sun Yat-sen University Cancer Center
Guangdong, Guangzhou, 510060, China
-
The George Washington Medical Faculty Associates
Washington D.C., District of Columbia, 20037, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Ear acupressure: a new weapon against chemotherapy side effects?
- Can a Custom-Made immune cell vaccine turn the tide against solid tumors?
- Can a new tracer light up tumors better than standard PET scans?
- Personalized weight loss coaching could help cancer survivors shed pounds
- New radiation implant shows promise for skin cancer
- Healthy volunteers needed to test new version of cancer drug